As Huntington’s Disease Awareness Month Commences, A New Drug Offers Hope To Pre-Symptomatic Sufferers
With May’s Huntington’s Disease Awareness Month as a backdrop, the Avicena Group, a California based biotech company, is set to launch a clinical trial for a new drug therapy, HD-02, with the ultimate aim of delaying the onset of this incurable, fatal disease. If successful, this compound would signal a significant advancement in the treatment of Huntington’s disease and finally provide hope for 150,000 Americans who are carriers of the deadly Huntington’s gene.
